Baxter

Baxter International has received approval from US Food and Drug Administration (FDA) for its Phoxillum Renal Replacement Solutions (BK4/2.5 and B22K4/0) to use as replacement solutions in continuous renal replacement therapy (CRRT).

The therapy aims to correct electrolyte and acid-base imbalances.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In addition, Phoxillum can be used in case of drug poisoning when CRRT is used to remove dialysable substances.

Baxter vice-president and renal therapeutic area lead Bruce Culleto said: "The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT.

"Phoxillum was developed to treat hypophosphatemia in patients with CRRT, and is said to be the only FDA approved pre-mixed solution containing phosphate in a 5l bag."

"Introducing products like Phoxillum is part of Baxter’s commitment to offering healthcare providers a range of therapy options for patients."

See Also:

Phoxillum was developed to treat hypophosphatemia in patients with CRRT, and is said to be the only FDA approved pre-mixed solution containing phosphate in a 5l bag.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to Baxter, Phoxillum will facilitate electrolyte management during CRRT, by allowing use of a single type of solution across a wide clinical spectrum of acute kidney injury (AKI) patients.

Developed for paediatric and adult patients, the approval comprises Phoxillum formulations containing different bicarbonate concentrations.

The company plans to start marketing of Phoxillum phosphate-containing solutions in the second quarter of 2015, in the US. Phoxillum also received orphan drug designation from FDA for use in CRRT.

Image: Baxter building in Vienna. Photo: courtesy of Gerd Fahrenhorst.